



# UNITED STATES PATENT AND TRADEMARK OFFICE

27

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/069,950	03/07/2002	Sophie Gaubert	02043	2908

23338 7590 02/08/2005

DENNISON, SCHULTZ, DOUGHERTY & MACDONALD  
1727 KING STREET  
SUITE 105  
ALEXANDRIA, VA 22314

EXAMINER

KISHORE, GOLLAMUDI S

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED: 02/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/069,950

Applicant(s)

GAUBERT ET AL.

Examiner

Gollamudi S Kishore, Ph.D

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 20 September 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 16-19, 21-33 and 35-65 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 16-19, 21-33 and 35-65 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

The amendment dated 9-20-04 is acknowledged.

Claims included in the prosecution are 16-19, 21-33 and 35-65.

### ***Claim Rejections - 35 USC § 103***

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 16-19, 21-33 and 35-65 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haan et al (Vaccines 13, no. 2, pp. 155-162, 1995) by itself or in combination with Doerschuk (5,702, 946) in further combination with Roux (5,908,697).

As discussed extensively in the previous action, Haan et al teach that intra-nasal administration of multilamellar vesicles containing influenza viral sub-units Results in an induction of both systemic IgG and secretory IgA responses compared with the antigen alone (abstract, Materials and Methods and Discussion section).

The reference of Doerschuk teaches the conventional techniques of purifying the immunoglobulins.

As also discussed before, Roux discloses active principle carriers containing lecithin (phospholipid) and sucrose ester and the other surfactants. The structures disclosed by Roux are multilamellar vesicles with an onion like structure having an internal liquid crystal structure formed by a stack of concentric bilayers. According to Roux, these vesicles have certain advantages, which include less sensitivity to bacterial contamination. The vesicles have diameters of 0.1 and 50 microns. The two surfactants according to Roux have HLB values between 3 and 7 and 8-15 respectively (abstract, col. 3, lines 4-27; col. 5, line 40 through col. 7, line 40; Examples and claims). What are lacking in Roux are the teachings of using an antigen as active principle and mucosal administration of the composition to elicit an immune response.

As discussed above, multilamellar liposomes have onion like structure with concentric lipid bilayers separated by aqueous medium. Assuming that Haan's multilamellar liposomes are different from instant liposomes, it is deemed obvious to use multi-lamellar liposomes containing lecithin and sucrose esters of Roux would have been obvious to one of ordinary skill in the art because of the advantages taught by Roux. Alternately, the use of antigen as the active principle and administer the composition of Roux mucosally, with a reasonable expectation of success, since the reference of Haan shows the enhancement of immune response when antigens are administered mucosally in multi-lamellar liposomes compared to antigen alone.

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant argues Haan (De Haan) requires a negatively charged phospholipid and beneficial results are not obtained utilizing a neutral or zwitterionic

Art Unit: 1615

phospholipid and that the instant invention does not require a negatively charged phospholipid. This argument is not found to be persuasive since instant claims do not recite this requirement. In fact, claim 16 does not recite any phospholipids at all.

Applicant's arguments that Haan requires that the vaccination protocol should enable reaching the totality of the pulmonary tract is not found to be persuasive since instant claim language does not exclude this protocol; instant claim 16 recites simply 'mucosal administration and the respiratory tract is layered with mucosal tissue. Applicant's arguments that in the experiments of Haan et al, the administration of empty liposomes two days before the antigen produced results as good as or even better than, the protocol in which the liposomes are administered together are not persuasive since according to applicant's own argument, the composition is effective when the antigen is incorporated in the composition. Applicant's arguments with regard to the mechanism of action discussed by Haan are confusing. First of all, the mechanism by which the antigen in Haan acts has no patentable significance. Secondly, if the antigen is liberated from the liposomes before reaching the lungs according to applicant, then wont the same alveolar macrophages capture the liberated antigen also? Applicant's arguments that one of ordinary skill in the art would not be motivated to use more stable liposomes as in instant invention (same as those taught by Roux) thus, are not found to be persuasive. It is the examiner's position that one of ordinary skill in the art would be motivated to use Roux's liposomes for the advantages taught by Roux. The rejection is maintained. Since the limitations in added claims are taught by Roux (which teaches the same claimed liposomes), the rejection is applicable to the added claims.

Art Unit: 1615

3. Claims 16-19, 21-33 and 35-65 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wassef et al (Immunomethods, 4, pp. 217-222, 1994) in combination with Haan et al (Vaccines 13, no. 2, pp. 155-162, 1995) by itself or in combination with Doerschuk (5,702, 946) and Roux (5,908,697) both cited above.

Wassef et al teach the successful use of multilamellar vesicles as carriers for vaccines (note abstract, pages 218-220). Wassef et al although teach that liposomal vaccines have been administered by many routes, they do not specifically teach mucosal route of administration. Wassef et al's disclosure also lacks specifics about multilamellar vesicles.

The teachings of Haan et al, and those of Doerschuk, and Roux have been discussed above.

The use of Roux's multilamellar vesicles for encapsulating an antigen and delivering the composition mucosally would have been obvious to one of ordinary skill in the art because of the advantages of such liposomes taught by Roux and the enhancement of the immune response when administered mucosally as seen from Haan et al.

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant's arguments with regard to Haan, Doerschuk and Roux have been discussed above. Applicant argues that Wassef et al teaches the use of phosphatidylcholine for the liposomes which cannot be used according to Haan. This argument is not found to be persuasive since as pointed out above, instant claims do not recite any specific phospholipids at all.

Upon consideration, other rejections made in the previous action are withdrawn.

4. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S Kishore, Ph.D whose telephone number is (571) 272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Gollamudi S Kishore, Ph.D  
Primary Examiner  
Art Unit 1615

GSK